Is Mantis profitable in 2026?

No. Mantis is a pre-revenue seed stage startup with no disclosed revenue figures. It raised a $7.4M seed round led by Decibel VC, announced March 30, 2026, and has only one anecdotal customer relationship, an NBA team, per TechCrunch.

How much funding has Mantis raised?

Mantis raised $7.4M in seed funding led by Decibel VC, with participation from Y Combinator, Liquid 2, and angels, reported by TechCrunch on March 30, 2026. A founder-stated 'seed 2' round targeted for March 2026 has no confirmed close as of July 2026.

Who is Mantis's biggest competitor?

Unlearn.AI is Mantis's closest direct peer, having raised a $50M Series B in April 2022 for FDA-qualified synthetic control arms in clinical trials, a four-year head start on the exact digital-twin use case Mantis pitched in March 2026.

Could AI replace Mantis's core product?

Possibly. Mantis's core pipeline routes multimodal data through general-purpose commercial LLMs before physics simulation, per TechCrunch's March 30, 2026 profile, meaning frontier model providers could commoditize that layer, leaving only its unproven physics engine as differentiation.

Who owns Mantis and who founded it?

Mantis is privately held and venture-backed. Founder and CEO Georgia Witchel holds degrees from Harvey Mudd, Johns Hopkins, and University of Washington, and previously built Louiza Labs, a surgical-robotics digital-twin startup that raised $5M in 2025.

Does Mantis have real paying customers?

The only customer relationship reported is anecdotal: Georgia Witchel told TechCrunch on March 30, 2026 that an NBA team uses Mantis's digital twins to track jump performance against sleep and training load. No named enterprise, pharma, or hospital logos have appeared in third-party reporting.

YC Winter 2026 · United States

Mantis

Early-stage startup building AI digital twins of humans from health data.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Silence or confirmation of the stated 'seed 2' funding round

The call

Mantis has repositioned three times in five months while Unlearn.AI already holds the FDA-qualified synthetic-trial-data room it is now chasing.

Mantis makes software that generates fake medical data or routes AI questions, but has switched its core story three times in five months, suggesting the company has not yet found a business that sticks. The real problem is that Unlearn.AI has been doing the exact same synthetic-data idea since 2022 with $50 million in funding and FDA approval already earned, while bigger players like Tempus and IQVIA own the actual medical datasets that pharma companies need. The one thing that could matter is if Mantis lands a real, signed contract with a major pharma or hospital (not just a handshake with an NBA team) and proves it can get FDA clearance for its data technology, which would show it is not just pivoting to chase trends.

Why

AI pressure: Frontier LLMs (OpenAI, Google, Anthropic) that power Mantis's own routing layer. Mantis's LLM layer sits on top of frontier models, so any lab that ships biomedical-grade reasoning erodes its core tech. Could AI do the core job? Yes, likely.

Bigger players: Unlearn.AI. Unlearn.AI already runs FDA-qualified synthetic control arms for trials, the exact use case Mantis pitched in March, with a four-year head start. Could a giant copy it? Yes, easily.

What protects it. None confirmed: no FDA filing, no contracted pharma or hospital customer, and the NBA relationship is still just a founder anecdote.

What would change this call

Whether Mantis announces a fourth business repositioning before end of 2026. Would show continued pre-product-market-fit search rather than a settled business.
Whether the 'seed 2' round Georgia Witchel described in Feb 2026 is confirmed by third parties by Q4 2026. Silence would suggest fundraising or investor-confidence struggles.
Whether Mantis names any pharma, hospital, or multi-team sports customer with a signed contract. Would convert the anecdotal NBA relationship into verifiable commercial traction.

Key numbers

$7.4M seed led by Decibel VC (2026-03-30)
One NBA team cited as client, no signed contract found (2026-03-30)
Mantis claims trials lose ~$15M each to bad data (2026-02-09)

Named risks

Repositioned core product three times within five months, Feb to mid-2026, no settled business model. Severity: high
No named enterprise or pharma customer, only one anecdotal NBA relationship as of March 2026. Severity: high
Core LLM routing layer built on general-purpose commercial LLMs, exposed to frontier-model commoditization. Severity: high
Unconfirmed 'seed 2' round stated for March 2026 with no independent confirmation of a close by July 2026. Severity: medium
Sensitive health-data brokerage positioning invites HIPAA, privacy, and bioethics scrutiny. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Unlearn.AI	losing to	Raised $50M Series B in 2022 for FDA-qualified synthetic control arms, 4-year head start over Mantis's March 2026 pitch
Tempus AI	contesting	Public since 2024 IPO, holds large clinical-molecular datasets and pharma integrations Mantis lacks
Truveta	contesting	Health-system-backed real-world-data cooperative with clinical data licensing as of March 2026
IQVIA	contesting	Over $45B market cap incumbent in clinical data and analytics as of March 2026
Tonic.ai and MDClone	contesting	General-purpose synthetic healthcare data platforms named as comparators, June 2026

Questions people ask

Is Mantis profitable in 2026?: No. Mantis is a pre-revenue seed stage startup with no disclosed revenue figures. It raised a $7.4M seed round led by Decibel VC, announced March 30, 2026, and has only one anecdotal customer relationship, an NBA team, per TechCrunch.
How much funding has Mantis raised?: Mantis raised $7.4M in seed funding led by Decibel VC, with participation from Y Combinator, Liquid 2, and angels, reported by TechCrunch on March 30, 2026. A founder-stated 'seed 2' round targeted for March 2026 has no confirmed close as of July 2026.
Who is Mantis's biggest competitor?: Unlearn.AI is Mantis's closest direct peer, having raised a $50M Series B in April 2022 for FDA-qualified synthetic control arms in clinical trials, a four-year head start on the exact digital-twin use case Mantis pitched in March 2026.
Could AI replace Mantis's core product?: Possibly. Mantis's core pipeline routes multimodal data through general-purpose commercial LLMs before physics simulation, per TechCrunch's March 30, 2026 profile, meaning frontier model providers could commoditize that layer, leaving only its unproven physics engine as differentiation.
Who owns Mantis and who founded it?: Mantis is privately held and venture-backed. Founder and CEO Georgia Witchel holds degrees from Harvey Mudd, Johns Hopkins, and University of Washington, and previously built Louiza Labs, a surgical-robotics digital-twin startup that raised $5M in 2025.
Does Mantis have real paying customers?: The only customer relationship reported is anecdotal: Georgia Witchel told TechCrunch on March 30, 2026 that an NBA team uses Mantis's digital twins to track jump performance against sleep and training load. No named enterprise, pharma, or hospital logos have appeared in third-party reporting.

Timeline

2026-07-08Seedtable lists Mantis at 3 employees and funding stage as Unknown, conflicting with reported seed
2026-06Mantis site repositions company as consumer 'OAuth for identity' data-broker model
2026-04-02TheAIInsider reports Mantis's $7.4M seed funding announcement
2026-03-30TechCrunch profiles Mantis as physics-based digital-twin generator, reveals NBA client and $7.4M seed
2026-03-12Authority Magazine interview notes founder publicly compared to Elizabeth Holmes
2026-02-11Founder states on LinkedIn that a 'seed 2' round is being raised in March 2026
2026-02-09YC Launch positions Mantis as 'Databricks for Biomedical and Clinical Data'
2025-09-19Founder's prior venture Louiza Labs reported to have raised $5M for surgical robotics

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

CellType OctaPulse The Token Company